Every 8-K that Enhabit, Inc. (EHAB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EHAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EHAB filings page.
Enhabit, Inc. has been acquired by Anchor Parent, LLC, an affiliate of Kinderhook Industries, and is becoming a privately held company. The deal values each share of common stock at $13.80 in cash, and the aggregate purchase price for all outstanding shares is approximately $762 million.
At the merger’s effective time, all Enhabit common shares were cancelled and converted into the right to receive the cash consideration, and trading on the NYSE was halted, with delisting and deregistration steps underway. Equity awards, including stock options, RSUs, RSAs and PSUs, were generally vested and cashed out based on the $13.80 per-share amount, with underwater options and certain unvested PSUs cancelled.
In connection with closing, Enhabit’s credit agreement was amended to add $105 million of incremental term loans, bringing total initial term loans to $420 million, and to increase revolving commitments by $40 million to $200 million. These obligations are guaranteed and secured by substantially all assets of the parent, merger subsidiary, Enhabit and certain subsidiaries. Enhabit’s prior board resigned and was replaced by the former Merger Sub directors, and the charter and bylaws were amended and restated.
Enhabit, Inc. reports that stockholders have approved its planned merger and go-private transaction. At a special meeting held on May 12, 2026, holders adopted the Agreement and Plan of Merger under which Anchor Merger Sub, Inc. will merge into Enhabit, which will become a wholly owned subsidiary of Anchor Parent, LLC.
As of the April 13, 2026 record date, 51,225,606 common shares were entitled to vote, and 36,341,102 shares (about 71%) were present, constituting a quorum. The merger proposal passed with 36,311,910 votes for, 18,275 against and 10,917 abstaining, and a separate advisory compensation proposal also received majority support. The parties intend to complete the merger on May 15, 2026, after satisfying customary closing conditions, after which Enhabit’s common stock will be delisted from the New York Stock Exchange and will no longer trade publicly.
Enhabit, Inc. reports progress on its pending sale to Kinderhook-affiliated funds. The U.S. Federal Trade Commission granted early termination of the Hart-Scott-Rodino antitrust waiting period on April 15, 2026, removing a key regulatory closing condition.
The special meeting of stockholders to vote on the merger with Anchor Parent, LLC is scheduled for May 12, 2026 at 8:00 a.m. Central Time. The company expects the merger to close in the second quarter of 2026, subject to remaining conditions, and is suspending earnings calls, guidance and a second-quarter 2026 earnings release while the transaction is pending.
Enhabit, Inc. reported solid fourth quarter and full-year 2025 results while highlighting its pending sale to Kinderhook Industries for $13.80 per share in cash, valuing the company at about $1.1 billion. Fourth quarter net service revenue was $270.4 million, up 4.7% year over year, with consolidated Adjusted EBITDA rising 11.6% to $28.0 million and Adjusted EBITDA margin improving to 10.4%.
The company still posted a GAAP net loss attributable to Enhabit of $38.7 million, or diluted loss per share of $0.76, driven in part by $47.7 million of goodwill and intangible asset impairments, but generated adjusted diluted EPS of $0.14. For 2025, revenue reached $1.06 billion, up 2.4%, and Adjusted EBITDA grew 8.4% to $108.5 million.
Home health net service revenue increased 3.2% in the quarter, with total admissions up 7.3% and cost per patient day down 3.5% year over year, while hospice revenue rose 10.0% on 9.9% growth in average daily census. Enhabit continued to strengthen its balance sheet, reducing total bank debt by $125.0 million since the end of 2023, achieving a 3.7x leverage ratio and realizing about $22 million in annualized cash interest savings. Adjusted free cash flow for 2025 was $71.2 million, up from $53.5 million in 2024. The Kinderhook merger is expected to close in the second quarter of 2026, subject to stockholder approval and customary conditions, and Enhabit has suspended earnings calls and financial guidance while the transaction is pending.
Enhabit, Inc. entered into an amended and restated credit agreement providing a $315 million Term Loan A Facility and a $160 million Revolving Credit Facility, both maturing five years from closing. Interest is based on SOFR or an alternate base rate plus a margin tied to Enhabit’s total net leverage ratio, with initial margins of 2.25% over SOFR and 1.25% over the base rate.
The term loan amortizes 7.50% per year in equal quarterly installments starting June 30, 2026, with the balance due at maturity. The revolving facility includes a $40 million letter of credit sublimit. Proceeds refinance Enhabit’s prior credit agreement, pay related fees and expenses, and support general corporate purposes.
The facilities are guaranteed by certain existing and future wholly owned domestic material subsidiaries and secured by first-priority liens on substantially all assets of Enhabit and the guarantors. Key financial covenants include a maximum total net leverage ratio of 4.50 to 1.00, with a permitted 0.50 step-up for specified material acquisitions, and a minimum fixed charge coverage ratio of 1.25 to 1.00.
Enhabit, Inc. reported that Senior Vice President and Chief Accounting Officer Collin McQuiddy has decided to resign, effective March 27, 2026. He will remain with the company until that date to help transition his responsibilities and is leaving to pursue another career opportunity.
The company stated there were no disagreements with Mr. McQuiddy regarding operations, policies, or practices. After the transition date, Chief Financial Officer Ryan Solomon will also serve as principal accounting officer until a successor is appointed, without any change or increase in his compensation.
Enhabit, Inc. agreed to be acquired by affiliates of Kinderhook Industries in an all‑cash merger at $13.80 per share. Each outstanding Enhabit common share (with limited exceptions) will be converted into the right to receive this cash amount at closing.
The deal implies a total enterprise value of about $1.1 billion and represents a 24.4% premium to Enhabit’s February 20, 2026 closing price and a 33.8% premium to its 60‑day volume‑weighted average price. After the merger, Enhabit will become a private company and its stock will be delisted from the New York Stock Exchange.
Equity awards will generally vest at the merger time and be cashed out at the $13.80 price, with out‑of‑the‑money options cancelled. Closing requires majority stockholder approval, antitrust and other regulatory clearances, and absence of a Company Material Adverse Effect, and is targeted for the second quarter of 2026.
Enhabit, Inc. filed a Form 8-K to share an update on a Delaware fiduciary duty case. Enhabit and Encompass Health Corporation have collected $43.1 million in full satisfaction of their claims for attorneys’ fees and mitigation damages from three individual defendants.
The companies will split the $43.1 million substantially equally. They also remain entitled, under a prior Court of Chancery order, to share 43% of VitalCaring Group’s ongoing profits and exit proceeds if and when VitalCaring is sold, through a constructive trust that is unchanged for the non-settling defendants.
Enhabit, Inc. filed a report stating that it will participate in the BofA Securities 2025 Home Care Conference on December 9, 2025, at 2:50 p.m. CT. President and CEO Barbara Jacobsmeyer and Chief Financial Officer Ryan Solomon will take part in a fireside chat.
They intend to discuss Enhabit’s strategic focus, recent business developments, and an update to anticipated pricing impacts for 2026, among other topics. An investor presentation supporting this discussion has been made available as Exhibit 99.1 and is incorporated by reference, though it is being furnished rather than filed, which limits its use for certain legal purposes.
Enhabit, Inc. furnished an 8-K announcing it issued a press release reporting financial results for the quarter ended September 30, 2025. The company also provided supplemental materials for its earnings discussion.
Exhibit 99.1 contains the earnings press release dated November 5, 2025, and Exhibit 99.2 includes supplemental information for the third quarter 2025 earnings call. The call is scheduled for 9:00 a.m. Eastern Time on Thursday, November 6, 2025. The materials under Items 2.02 and 7.01 are being furnished, not filed.
Enhabit, Inc. filed a current report describing an upcoming investor-focused appearance by its leadership team. President and Chief Executive Officer Barbara Jacobsmeyer and Chief Financial Officer Ryan Solomon will take part in a fireside chat at the Jefferies 2025 Healthcare Services Conference on September 30, 2025, at 10:55 a.m. Central Time. The session will be webcast live and available for replay through the company’s investor relations website at https://investors.ehab.com.
The company has also prepared an investor presentation for this event and attached it as Exhibit 99.1. This presentation is being furnished under Regulation FD, meaning it is provided for informational purposes and is not deemed filed for liability purposes under the securities laws unless later specifically incorporated by reference.
Enhabit (NYSE:EHAB) filed an 8-K reporting results of its 26 June 2025 annual meeting. Shareholders approved the 2025 Equity & Incentive Compensation Plan, reserving up to 3.3 million shares (≈6.5% of the 50.6 million outstanding) for options, RSUs and performance awards. The plan, administered by the Compensation & Human Capital Committee, includes a $750k annual cap on non-employee director pay and allows performance metrics spanning EBITDA, revenue and quality-of-care. All 10 directors were re-elected, PwC was ratified as auditor and the say-on-pay resolution passed. Support for the equity plan was strong at 31.0 M for vs 0.4 M against. While the plan aligns incentives, it introduces potential dilution and higher stock-based compensation expense.